Clovis Close To Bankruptcy As Cancer Drug Outlook Worsens
Rubraca Revenues Are Shrinking
Executive Summary
Troubles are mounting for Clovis and its PARP inhibitor Rubraca, and now the company looks to be just months from bankruptcy.
You may also be interested in...
Junshi/IMPACT’s Senaparib Faces Crowded PARP Inhibitor Field
The companies said their Phase III ovarian cancer study met its primary endpoint, but the market for PARP inhibitors has come under domination by Lynparza and Zejula.
Can Lynparza Hold On As PARP Inhibitors Enter First-Line Prostate Cancer Market?
AstraZeneca, Pfizer and Johnson & Johnson are presenting Phase III data for PARP inhibitors combined with anti-androgen drugs in first-line mCRPC, a potential blockbuster opportunity.
Stock Watch: Post-Pandemic Drug Commercialization Shifts
Emerging from the pandemic after nearly three years, therapy areas and drug classes are traveling at different speeds.